Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Surveying U.S. Cosmetic Products For Asbestos-Contaminated Talc

This article was originally published in The Rose Sheet

Executive Summary

FDA is reviewing talc and talc-containing cosmetic products on the U.S. market for asbestos contamination following reports of the carcinogen in cosmetics overseas, according to an FDA spokesman

You may also be interested in...



Heavy Metals, Estrogenics Among Research Priorities For FDA's Cosmetics Office

FDA’s Office of Cosmetics and Colors continues with surveys to detect the presence of controversial ingredients in cosmetics, including asbestos in talc-containing products. Office’s Deputy Director Patricia Hansen provides an overview at the Personal Care Products Council’s recent scientific summit.

FDA: No Asbestos Found In Talc Products Sampled, But Results Limited

Following reports of asbestos in talc and talc-containing products overseas, FDA conducted a survey of suppliers and products on the U.S. market, finding no detectable levels of asbestos.

CIR Expert Panel Set To Make Final Formaldehyde Recommendations Sept. 27

The Cosmetic Ingredient Review Expert Panel could issue a final safety assessment for formaldehyde and methylene glycol at its Sept. 27 meeting.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016788

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel